Aesthetic medicine of the new generation

M1 Akademie

In-house training and development is a key element of the M1 Group's business model. That is why M1 operates the M1 Akademie. The main topics of the training courses provided are new treatment procedures, innovations and product presentations in the fields of aesthetic medicine as well as plastic and aesthetic surgery. Due to this uniform training and further education of all doctors and medical staff, M1 is able to offer customers the highest quality regardless of location.

M1 Akademie at a glance:

  • Worldwide private training centre for physicians, specialists and dentists
  • Neueste Behandlungsverfahren, Innovationen und
  • Latest treatment procedures, innovations and product presentations for the areas:
    • Aesthetic medicine
    • Plastic and aesthetic surgery
  • Providing practical experience, different techniques and detailed complication management
  • Brain pool with many years of know-how
  • Represented in Germany, Austria, Switzerland, the Netherlands, UK and Australia

We provide quality, techniques and expertise to doctors

More about M1 Akademie

Latest news

| Investor News

  • Group revenue falls to just under EUR 139 million (EUR 165 million in H1-2021)
  • Group EBITDA amounts to EUR 7.4 million (previous year: EUR 9.9 million); EBIT amounts to EUR 4.5 million (previous year: EUR 7.1 million)
  • Beauty: Increase in treatment and sales figures; five new centres already opened in 2022; no influence of the deteriorating consumer climate so far

| Investor News

  • Group turnover falls to EUR 63.5 million (EUR 80.8 million in Q1-2021)
  • Group EBITDA amounts to EUR 4.2 million (previous year: EUR 4.0 million); EBIT amounts to EUR 2.8 million (previous year: EUR 2.6 million)
  • Beauty: Increase in turnover by 6 % to EUR 13.8 million (previous year: EUR 13.0 million); number of treatments rises by 9 % to almost 89 thousand.
  • Trade: Continuation of operational optimisations and portfolio streamlining

| Investor News

  • Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
  • Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
  • The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.

| Investor News

M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.